Combating the “Silent Killer”: How Atrasentan is Redefining Primary IgA Nephropathy Treatment and Altering the Course to Kidney Failure
🤔 In China, what is the most common primary glomerulonephritis leading to kidney failure in…
News
2025 in Review丨Dual Harvest for China Innovative Drugs — How R&D Leadership Met Capital Validation
The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed…
From Generics to Bio-Engineering: How China is Redesigning the Future of Medicine
For decades, “Made in China” in pharmaceuticals conjured images of generic drugs and manufacturing scale.…
Tibremciclib Capsules Granted Regulatory Approval in China for Advanced Breast Cancer Patients
The National Medical Products Administration (NMPA) of China has officially approved Tibremciclib Capsules (BPI-16350, brand…
New COPD Treatment Launched: What’s New in 2025 and What’s Next for Global and China COPD Care
🫁 Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow…
Primary Hypertension Treatment Made Simple: What It Is and Key Medication Options Featuring SPH3127 Tablets
Primary hypertension remains one of the most widespread chronic conditions globally. 👉 Currently, approximately 1.2…
Mazdutide Injection Approved as China’s First Dual-Action Metabolic Agonist Targeting GLP-1 and GCG
The National Medical Products Administration (NMPA) has officially approved the marketing application for Mazdutide Injection…
Erlotinib Hydrochloride Tablets: A Foundational Milestone in the Era of EGFR-Targeted Therapy
In the fast-evolving landscape of lung cancer treatment, targeted therapies have reshaped the meaning of…
Anti-Tumor Therapies: Key Drugs and Modern Cancer Treatment Approaches
Cancer remains one of the most significant global health challenges, affecting millions of people every…
Why Omega-3-Acid Ethyl Esters Matter: A Clinically Tested Solution for Severe Hypertriglyceridemia
🍔 In recent years, the prevalence of metabolic disorders has continued to rise, driven by…